Oncology physicians and nurses at UCLA's Jonsson Cancer Center will experience the extreme fatigue their patients feel during a unique training session Monday, Oct. 26, using a virtual reality simulator that lets health care workers walk in a cancer patient's shoes.
Physicians at UCLA's Jonsson Cancer Center today launched a new experimental treatment for inoperable pancreatic cancer using a form of a virus that causes the common cold.
The breakthrough breast cancer drug Herceptin was approved late Friday by the U.S. Food and Drug Administration, the first in an expected wave of new therapies that will attempt to beat back cancer by attacking the disease at its genetic roots. Herceptin was developed in a joint effort of UCLA's Jonsson Cancer Center and the biotechnology company Genentech, Inc., of South San Francisco.
Calling it the most significant advance in radiosurgery technology in a decade, physicians at UCLA's Jonsson Cancer Center today opened the first facility in the US offering BrainLAB's Novalis -- a shaped beam surgery system designed to treat brain tumors.
The first custom sacrum prosthetic implant operation of its kind in the United States has been successfully performed by three UCLA doctors. The doctors have successfully rejoined a patient's pelvis to her lumbar spine with an innovative prosthetic device produced by Howmedica, Inc., of Rutherford, New Jersey. The doctors implanted a prosthesis in the patient, a 49-year-old woman (Tulare, Calif.) whose sacrum -- known as the tailbone -- had been destroyed by a giant cell tumor.
An advisory panel for the U.S. Food and Drug Administration (FDA) today recommended approval of the breast cancer drug Herceptin, the first cancer drug to successfully treat a specific genetic alteration. The FDA's Oncologic Drugs Advisory Committee recommended Herceptin for approval as a single agent and in combination with Taxol.
UCLA Medical Center's Heart Transplant Program announced on May 5 that it has reached a collaborative agreement to begin training its surgeons and staff to install a battery-powered artificial heart replacement device developed and manufactured by ABIOMED, Inc.
A chemical associated with tuberculosis may substantially reduce the amount of damage sustained from a heart attack, a finding that could lead to new treatment for heart attack victims, according to a new study. The finding was made by two physician brothers in different disciplines who happened to discuss their individual research at a family gathering. Serendipity at its best.
A new UCLA study has revealed that many physicians may lack the training necessary to interpret CT scans and safely identify stroke patients who may benefit from "clot-busting" drug therapies.
UCLA researchers have isolated a unique naturally-occurring antibiotic from the femalse urinary and reproductive systems, which could lead to novel treatments for a variety of common infections including pelvic inflammatory disease, urinary tract and vaginal infections.
Benign, non-cancerous brain tumors, called meningiomas, can impair brain function and even kill. So UCLA medical researchers have begun testing a new form of chemotherapy to treat them.
A temporary heart device used by cardiac doctors at UCLA Medical Center saved a 24-year-old patient dying from heart failure. The cardiac-assist device avoided the need for an emergency heart transplant.
A UCLA orthopedic surgeon has developed a new technique to treat bone death in human hips that early results suggest may prevent the need for a total hip replacement. Called osteoregeneration, the procedure implants a capsule filled with bone-morphogenetic protein (BMP) that induces the body to grow new bone. Only UCLA offers BMP and the attendant procedure.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right